Candesartan cilexetil - A review of effects on cardiovascular complications in hypertension and chronic heart failure

Current Medical Research and Opinion

Volumn 23, Issue 7, 2007, Pages 1693-1705

  Meredith, Peter A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Candesartan; Cardiovascular disease; Heart failure; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; VALSARTAN;

ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE TITRATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; META ANALYSIS; REVIEW; STROKE; SYSTEMATIC REVIEW; UNITED KINGDOM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; TETRAZOLES;

EID: 34547184060     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210723     Document Type: Review

References (126)

1. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
2. Petersen S, Peto V, Rayner M, et al. European cardiovascular disease statistics [online]. Available from The British Heart Foundation, London
3. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [online]. Available from www.circulationaha. org
4. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-63
5. Trenkwalder P. Preventing the cardiovascular complications of hypertension. Eur Heart J Suppl 2004;6:H37-H42
6. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 2005;23(Suppl): S9-S17
7. Black HR. The burden of cardiovascular disease: following the link from hypertension to myocardial infarction and heart failure. Am J Hypertens 2003;16:4S-6S
8. Moser M, Herbert P. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-8
9. Sjoholm A. ALLHAT: a critical assessment. Blood Press 2004;13:75-9
10. Leenen FH. ALLHAT: what has it taught us so far? Can Med Assoc J 2004;171:719-20
11. Weber MA. Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens Suppl 2006;24: S37-S44
12. 1 receptor in the cardiovascular continuum. Eur Heart J Suppl 2004;6:H3-H9
13. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-C97
14. 2 receptor comes of age. Hypertension 2005;45:840-4
15. Nicholls MG, Charles CJ, Crozier IG, et al. Blockade of the renin-angiotensin system. J Hypertens Suppl 1994;12:S95-S103
16. Massie BM. Angiotensin-converting enzyme inhibitors as cardioprotective agents. Am J Cardiol 1992;70:101-171
17. Johnston CI. Treatment of hypertension with angiotensin converting enzyme inhibitors. Aust New Zealand J Med 1984;14:509-13
18. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994;127:1388-401
19. Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens 1999;12:189S-194S
20. Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005;19:331-9
21. Meredith PA. ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertension. Heart 2000;84(Suppl 1): i39-i41
22. Gavras HP. Issues in hypertension: drug tolerability and special populations. Am J Hypertens 2001;14:231S-236S
23. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42
24. Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatol 1980;116:902-5
25. Robertson JI, Tillman DM, Ball SG, Lever AF. Angiotensin converting enzyme inhibition in hypertension. J Hypertens Suppl 1987;5:S19-S25
26. Warner NJ, Rush JE. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 1988;35(Suppl 5):89-97
27. Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. Am J Med 1986;81: 46-50
28. Vleeming W, van Amsterdam JG, Strieker BH, de Wildt DJ. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 1998;18:171-88
29. Dykewicz MS. Cough and angioedema from angiotensin-converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol 2004;4: 267-70
30. Gavras H. Update on the clinical pharmacology of candesartan cilexetil. Am J Hypertens 2000;13:25S-30S
31. Stoukides CA, McVoy HJ, Kaul AF. Candesartan cilexetil: an angiotensin II receptor blocker. Ann Pharmacother 1999;33:1287-98
32. Ruilope LM, Rosei EA, Bakris GL, et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005;14:196-209
33. Meredith P, Ostergren J. From hypertension to heart failure - are there better primary prevention strategies? J Renin Angiotensin Aldosterone Syst 2006;7:64-73
34. Meredith P, Perloff D, Mancia G, Pickering T. Blood pressure variability and its implications for antihypertensive therapy. Blood Pressure 1995;4:5-11
35. Bonner G, Fuchs W. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension. Curr Med Res Opin 2005;21:935-40
36. Elliott HL. Trough:peak ratio and twenty-four-hour blood pressure control. J Hypertens Suppl 1994;12:S29-S33
37. Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46
38. Sever PS. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. J Hum Hypertens 1999;13(Suppl 1):S3-S10
39. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998;7:53-9
40. Meredith P. Achieving quality 24-h blood pressure control with candesartan cilexetil. Blood Press Suppl 2000;1:23-6
41. Gleiter CH, Jagle C, Gresser U, Morike K. Candesartan. Cardiovasc Drug Rev 2004;22:263-84
42. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997;11:S49-S53
43. Meineke I, Feltkamp H, Hogemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. Eur J Clin Pharmacol 1997;53:221-8
44. Bell TP, DeQuattro V, Lasseter KC, et al. Effective dose range of candesartan cilexetil for systemic hypertension [Candesartan Cilexetil Study Investigators]. Am J Cardiol 1999;83: 272-5, A6
45. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension [Candesartan Cilexetil Study Investigators]. Am J Cardiol 1998;82:961-5
46. Meredith P. Modern strategies in hypertension management. Eur Heart J Suppl 2004;6:H23-H29
47. Sever PS. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. J Hypertens Suppl 1997;15: S9-S12
48. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study [Candesartan/Losartan study investigators]. Am J Hypertens 1999;12:1181-7
49. Gohlke P, Jurgensen T, von Kugelgen S, Unger T. Candesartan cilexetil: development and preclinical studies. Drugs Today (Barc) 1999;35:105-15
50. Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl 2006;24:S23-S30
51. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12
52. 1-receptor blockers. Differences in potency and efficacy. Blood Press 2002;11:293-301
53. 1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. Blood Press 2002;11:244-52
54. Bakris G, Gradman A, Reif M, et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 2001;3:16-21
55. Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension [Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group]. Heart Dis 1999;1:52-7
56. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006;26:185-93
57. Eguchi K, Kario K, Shimada K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol 2003;92:621-4
58. Morgan T, Anderson A, Bertram D, MacInnis RJ. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 2004;5:64-71
59. Arakawa K, Ogihara T, Iimura O, et al. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension - a double-blind, parallel group-comparison study using enalapril maleate as control drug. J Clin Ther Med 1996;12:2613-61
60. Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997;11(Suppl 2): S61-S62
61. Zanchetti A, Omboni S, Di Biagio C. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension. J Hum Hypertens 1997;11 (Suppl 2): S57-S59
62. Cuspidi C, Muiesan ML, Valagussa L, et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002;20:2293-300
63. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A, et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press 2001;10:43-51
64. 1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000;13:504-11
65. Farsang C, Kawecka-Jaszcz K, Langan J, et al. Antihypertensive effects and tolerability of candesartan alone and in combination with amlodipine. Clin Drug Invest 2001;21:17-23
66. Imbs JL, Nisse-Durgeat S. Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients. Int J Clin Pract 2005;59:78-84
67. NICE/BHS. Clinical guideline 34: hypertension. Management of hypertension in adults in primary care: Partial update [online]. Available from http://www.nice.org.uk/CG034guidance [accessed 28 June 2006]
68. European Society of Hypertension-European Society of Cardiology. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
69. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs 2005;5: 171-83
70. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS study. Clin Drug Invest 2000;19:239-46
71. Ohman KP, Milon H, Valnes K. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension - comparison with a combination of losartan and hydrochlorothiazide. Blood Press 2000;9:214-20
72. Morgan T, Anderson A. A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002;15:544-9
73. Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005;28:273-7
74. Izzo Jr JL, Weinberg MS, Hainer JW, et al. Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials. J Clin Hypertens (Greenwich) 2004;6:485-93
75. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100
76. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74
77. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000;321: 1440-4
78. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. J Am Med Assoc 2002;287:1003-10
79. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289:2560-72
80. Thijs L, Den Hond E, Nawrot T, Staessen JA. Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Rev Cardiovasc Ther 2004;2:761-9
81. McInnes GT, O'Kane KPJ, Jonker J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997;11:S75-S80
82. Hansson L, Lithell H, Skoog I, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999;8: 177-83
83. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
84. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J Hypertens 2004;22:1605-12
85. Asmar R, Nisse-Durgeat S. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study. Vasc Health Risk Manag 2006;2:317-23
86. Dickstein K. ELITE II and Val-HeFT are different trials: together what do they tell us? Curr Control Trials Cardiovasc Med 2001;2:240-3
87. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66
88. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362: 772-6
89. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71
90. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-81
91. McMurray JJ, Young JB, Dunlap ME, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. Am Heart J 2006;151:985-91
92. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-26
93. O'Meara E, Solomon S, McMurray J, et al. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2004;25:1920-6
94. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-74
95. Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112:48-53
96. Dwyer MS, Melton III LJ, Ballard DJ, et al. Incidence of diabetic retinopathy and blindness: a population-based study in Rochester, Minnesota. Diabetes Care 1985;8:316-22
97. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6
98. Kohner E, Allwinkle J, Andrews J, et al. Report of the Visual Handicap Group. Diabetic Med 1996;13:S13-S26
99. Chaturvedi N, Sjolie AK, Svensson A. The Diabetic Retinopathy Candesartan Trials (DIRECT) programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 2002;3:255-61
100. The DIRECT Programme Study Group. The Diabetic Retinopathy Candesartan Trials (DIRECT) programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst 2005;6:25-32
101. Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens 2003;12:317-22
102. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006;21:2507-12
103. 1-receptor blockade on cardiovascular structure and function. Eur Heart J Suppl 2004;6:H17-H21
104. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93
105. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5
106. Kilander L, Nyman H, Boberg M, et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780-6
107. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74
108. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141-5
109. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
110. Degl'Innocenti A, Elmfeldt D, Hofman A, et al. Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). J Hum Hypertens 2004;18:239-45
111. Meredith PA, Murray LS, McMurray JJ. A putative placebo comparison of the SCOPE and LIFE trials. J Renin Angiotensin Aldosterone Syst 2004;5:59-63
112. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34:1699-703
113. Scandinavian Candesartan Acute Stroke Trial; 2007
114. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertension patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
115. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001;345:861-9
116. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006;114:838-54
117. Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation 2006;114:855-60
118. McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. Br Med J 2005;331:873
119. Ariff B, Zambanini A, Vamadeva S, et al. Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension. Stroke 2006;37:2381-4
120. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52
121. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995;98:476-84
122. Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-6
123. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006;151:985-91
124. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. J Am Coll Cardiol 2006;47:1997-2004
125. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2006
126. McMurray J, Andersson FL, Stewart S, et al. Resource utilization and costs in the Cadesartan in the Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006;27:1447-58